The Effect of Gefitinib on Treatment Necessity and Prognosis of NSCLC Patients with Early EGFR Mutations

Table 1

Clinical features.

—	Name	No recurrence n (%)	Recurrence n (%)
Gender	Male	26 (63.41)	15 (36.59)	9.148	0.002
	Female	17 (32.08)	36 (67.92)
Age	Under 60 years old	22 (40.00)	33 (60.00)	1.763	0.184
	60 years old and above	21 (53.85)	18 (46.15)
Alcohol consumption	No	28 (50.91)	27 (49.09)	1.425	0.233
	Yes	15 (38.46)	24 (61.54)
Smoking	No	32 (57.14)	24 (42.86)	7.251	0.007
	Yes	11 (28.95)	27 (71.05)
Family medical history	No	29 (48.33)	31 (51.67)	0.448	0.503
	Yes	14 (41.18)	20 (58.82)